Ji Cao, Ph.D., is a leading scholar in tumor pharmacology and anticancer drug discovery, internationally recognized as a World’s Top 2% Scientist (Stanford ranking, 2023) and a National Young Top Talent of China. His research integrates tumor pharmacology, chemical biology, and artificial intelligence–driven drug design, with major contributions to targeted protein degradation (PROTACs), ferroptosis regulation, MYC oncoprotein inhibition, and cancer immunotherapy. He has published over 59 peer-reviewed articles in high-impact journals such as Cell Metabolism, Nature Communications, PNAS, and Science Advances, including multiple ESI highly cited papers, accumulating more than 4,000 citations with an h-index of 36. His work has translated into innovation through 18 Chinese patents and one international patent. He has led nationally and provincially funded projects exceeding ¥14 million and has received prestigious science and technology awards for outstanding contributions to biomedical research and translational pharmacology.
Citation Metrics (Scopus)
6000
4000
2000
200
100
50
0
Citations
Documents
h-index
Featured Publication